Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Olma

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Nature|April 12, 1984
Carboxy terminus of vasopressin required for activity but not bindingM Manning, A Olma, W Klis, et al.
Journal of Neuroendocrinology|March 2, 2012
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeuticsM Manning, A Misicka, A Olma, et al.
Journal of Medicinal Chemistry|November 1, 1990
Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressinM Manning, S Stoev, A Kolodziejczyk, et al.
International Journal of Peptide and Protein Research|December 1, 1988
Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressinM Manning, W A Klis, M Kruszynski, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 14, 1999
An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acidsS Stoev, L L Cheng, A Olma, et al.
Journal of Medicinal Chemistry|May 12, 1995
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonistsM Manning, L L Cheng, W A Klis, et al.
Nature|October 4, 1987
No requirements of cyclic conformation of antagonists in binding to vasopressin receptorsM Manning, J P Przybylski, A Olma, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|January 1, 1997
Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonistsM Manning, L L Cheng, S Stoev, et al.
Journal of Medicinal Chemistry|December 1, 1987
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptorsM Manning, A Misicka, A Olma, et al.
Journal of Medicinal Chemistry|February 1, 1989
Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocinM Manning, M Kruszynski, K Bankowski, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Nature|April 12, 1984
Carboxy terminus of vasopressin required for activity but not bindingM Manning, A Olma, W Klis, et al.
Journal of Neuroendocrinology|March 2, 2012
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeuticsM Manning, A Misicka, A Olma, et al.
Journal of Medicinal Chemistry|November 1, 1990
Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressinM Manning, S Stoev, A Kolodziejczyk, et al.
International Journal of Peptide and Protein Research|December 1, 1988
Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressinM Manning, W A Klis, M Kruszynski, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 14, 1999
An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acidsS Stoev, L L Cheng, A Olma, et al.
Journal of Medicinal Chemistry|May 12, 1995
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonistsM Manning, L L Cheng, W A Klis, et al.
Nature|October 4, 1987
No requirements of cyclic conformation of antagonists in binding to vasopressin receptorsM Manning, J P Przybylski, A Olma, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|January 1, 1997
Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonistsM Manning, L L Cheng, S Stoev, et al.
Journal of Medicinal Chemistry|December 1, 1987
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptorsM Manning, A Misicka, A Olma, et al.
Journal of Medicinal Chemistry|February 1, 1989
Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocinM Manning, M Kruszynski, K Bankowski, et al.
Pageof 2